May 18, 2023
A Closing Thought
32
5
Even with exciting advancements, stakeholders must remain diligent in choosing data platforms.
May 17, 2023
Feature Articles
32
5
The value of electronic patient-reported outcomes data in this disease setting.
May 17, 2023
Feature Articles
32
5
Senior leaders gather to share insights on the increased investment in real-world data to boost the quality and efficiency of drug development—as the industry begins to more widely embrace evidence of proven outcomes in aiding approaches in clinical trial design, patient engagement, regulatory decision-making, and other areas.
May 16, 2023
Feature Articles
32
5
Examining the two areas of weakness cited in FDA draft guidance.
May 15, 2023
Feature Articles
32
5
‘No longer just a cool technology,’ efforts to validate these signals are evolving.
May 15, 2023
Data Collection
32
5
Remembering Steve Raymond, PhD, "the Godfather of ePRO."
May 15, 2023
Q&A
32
5
Cristina Varner, LUTCF, ARM, SVP/national life science and digital health & telemedicine practice leader at insurance brokerage Newfront explains the nuances of insuring clinical trials in today's growing digital health climate and the newer risks in areas such as cybersecurity that developers are facing.
May 12, 2023
From the Editor
32
5
Insights from recent industry events clear path for companies to identify how their internal practices could be harming the environment.
April 24, 2023
View from Brussels
32
5
Grading the government’s formal response to reform efforts hopeful of boosting UK’s sagging global standing in drug development.
March 30, 2023
View from Washington
32
5
Impact areas that will be closely watched during phase-out include drug testing and authorization, telehealth, and patient access.